+91 9425150513 (Asia) support@24lifesciences.com
Size, Share & Industry Analysis, By Product Type (Hard Capsules, Soft Capsules), By Shell Material (Gelatin, HPMC / Cellulose, Pullulan, Other Plant-based / Specialty Polymers), By Release Profile (Immediate Release, Delayed Release / Enteric, Extended / Modified Release), By Application (Prescription Pharmaceuticals, OTC Medicines, Nutraceutical / Healthcare Products, Hospital / Specialty Formulations), and Regional Forecast, 2026-2034
Explore the report section by section.
The global Medicinal Capsules market was valued at USD 2.50 billion in 2025 and is estimated at USD 2.64 billion in 2026. The market is projected to reach USD 4.10 billion by 2034, exhibiting a 5.7% CAGR during 2026–2034.
Medicinal capsules are oral solid dosage forms in which active pharmaceutical ingredients and excipients are enclosed within a hard or soft soluble shell. The commercial market includes hard gelatin capsules, plant-based hard capsules such as hydroxypropyl methylcellulose (HPMC) and pullulan systems, and soft capsules used for liquids, oils, suspensions and poorly soluble formulations. Capsules are widely used because they combine dose precision, taste masking, flexible fill options and patient-friendly administration.
Hard capsules form the largest product segment because they can accommodate powders, pellets, granules, mini-tablets and selected liquid or semi-solid fills across prescription, over-the-counter and nutraceutical applications. FDA's current Structured Product Labeling terminology recognizes multiple capsule dosage forms, including ordinary capsules, delayed-release capsules, extended-release capsules and liquid-filled capsules, illustrating the breadth of pharmaceutical use.
The technology mix is shifting toward plant-based and functional shells. Lonza's current portfolio spans gelatin and plant-based Capsugel products with different release profiles, while its 2025 Organicaps launch introduced a USDA organic-certified plant-based immediate-release pullulan capsule in North America. ACG has expanded its HPMC and pullulan range across immediate-release, liquid-fill, delayed-release and dry-powder-inhalation applications, increasing the strategic importance of polymer selection and shell functionality.
The study covers medicinal hard and soft capsule shells used to manufacture pharmaceutical and health-product dosage forms, including gelatin and plant-based technologies.
| Report Attribute | Coverage |
|---|---|
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026–2034 |
| Market Measurement | Revenue, USD billion |
| By Product Type | Hard Capsules; Soft Capsules |
| By Shell Material | Gelatin; HPMC / Cellulose; Pullulan; Other Plant-based / Specialty Polymers |
| By Release Profile | Immediate Release; Delayed Release / Enteric; Extended / Modified Release |
| By Application | Prescription Pharmaceuticals; OTC Medicines; Nutraceutical / Healthcare Products; Hospital / Institutional Use |
| By Fill Type | Powders & Granules; Pellets / Mini-tablets; Liquids & Semi-solids; Combination Fills |
| By Region | North America; Europe; Asia-Pacific; Latin America; Middle East & Africa |
| Key Market Players | Lonza / Capsugel; ACG Capsules; Qualicaps; Natural Capsules Limited; Farmacapsulas; Healthcaps India Ltd.; Jyoti Capsulations; Erawat Pharma Limited; Suheung; CapsCanada |
Capsules remain a standard oral dosage platform for branded, generic and specialty medicines. Growth in global pharmaceutical production directly increases demand for hard-shell capsules used in routine solid-dose manufacturing and for specialized capsule systems used in more complex products.
Capsules can improve taste masking and swallowing compared with some large tablets and can simplify administration of multiparticulate fills. These advantages are commercially important in chronic therapy, geriatric treatment and formulations where patient acceptability influences adherence.
HPMC and pullulan capsules address vegan, religious and clean-label preferences while also offering technical advantages for moisture-sensitive and hygroscopic ingredients. Their lower inherent moisture and resistance to gelatin cross-linking expand use in demanding pharmaceutical formulations.
Gelatin quality, cellulose derivatives, coloring systems and moisture control must remain consistent across very large production volumes. Capsule buyers therefore evaluate dimensional consistency, machinability, dissolution, regulatory documentation and supply continuity rather than price alone.
Tablets, orally disintegrating formats, sachets and liquid products can compete with capsules depending on dose, stability and patient needs. Capsule suppliers must differentiate through release functionality, fill versatility, customization and manufacturing efficiency.
Lonza launched Organicaps in 2025 as a USDA organic-certified plant-based pullulan capsule for the North American market. This signals a broader shift from simple animal-free positioning toward verified organic, non-GMO and clean-label differentiation.
Enteric capsule technologies such as Lonza Enprotect and ACG HX are designed to protect acid-sensitive payloads and release later in the gastrointestinal tract. Functional shells can reduce or eliminate additional coating steps in selected products.
ACG HL and similar systems allow liquids, semi-solids, gels and hot melts to be filled into HPMC hard capsules. This can improve delivery of poorly soluble or high-potency compounds while retaining the familiar two-piece capsule format.
Lonza's 2025 ACHIEV platform upgrade added a product configurator that helps customers select and customize capsules while accessing quality and regulatory documentation, illustrating how digital services are being layered onto physical capsule supply.
India and China continue to expand pharmaceutical and nutraceutical manufacturing, increasing local demand for empty capsules. Regional companies compete strongly on cost while global suppliers invest in local-for-local capacity and technical support.
Capsule performance depends on shell polymer, moisture content, dissolution behavior, mechanical properties, sealing compatibility and the physical characteristics of the fill.
| Capsule Technology | Functional Role | Commercial Significance |
|---|---|---|
| Hard gelatin capsules | Two-piece shells for powders, granules, pellets and many standard oral formulations. | Largest established format with high-speed filling compatibility and broad regulatory familiarity. |
| HPMC capsules | Plant-based shells with low moisture and strong stability across heat/humidity conditions. | Fast-growing pharmaceutical and nutraceutical alternative to gelatin. |
| Pullulan capsules | Plant-based polysaccharide shell with oxygen-barrier and clean-label positioning. | Premium segment for organic, vegan and oxidation-sensitive formulations. |
| Delayed-release capsules | Shell provides acid resistance and later intestinal release. | Can simplify enteric formulation and protect acid-sensitive APIs. |
| Liquid-filled hard capsules | Hard shell designed for liquids, semi-solids, gels and hot-melt fills. | Supports poorly soluble and high-potency formulations. |
| Soft capsules | One-piece gelatin or non-gelatin shell around liquids/oils/suspensions. | Strong in nutraceuticals, vitamins and lipid-based pharmaceutical delivery. |
Hard Capsules hold the majority share because of their broad formulation compatibility and high-volume use in prescription and OTC solid-dose manufacturing. Soft Capsules remain strategically important for liquid and lipid-based fills.
Hard two-piece capsules are widely used for powders, granules, pellets, mini-tablets and selected liquid formulations. Their modular shell/fill structure supports large-scale generic production and customized release technologies.
Soft capsules are well suited to oils, vitamins, lipophilic APIs and suspensions. Their one-piece sealed design supports dose uniformity and tamper resistance but requires specialized encapsulation equipment.
Gelatin remains the dominant shell material, while HPMC and pullulan are gaining share because of dietary, stability and formulation advantages.
Gelatin capsules have decades of pharmaceutical use, strong machinability and predictable dissolution. They remain cost competitive and dominate high-volume conventional applications.
HPMC capsules provide low moisture, heat stability and freedom from animal-derived ingredients. ACG specifies 3.0%–8.0% moisture for its current HPMC capsule platforms.
Pullulan offers strong oxygen-barrier properties and clean-label potential. Lonza's Organicaps 2025 launch demonstrates increasing commercial investment in this segment.
Other polymers and blends are used for targeted dissolution, modified release, inhalation and specialized formulation requirements.
Immediate Release remains the largest profile, while delayed-release and other functional shells are expanding as capsule technology takes on more of the drug-delivery role.
Most conventional hard and soft capsules are designed to disintegrate promptly after administration. This broad applicability keeps immediate release dominant.
Enteric capsule systems protect payloads through gastric transit and release in the intestine. They are relevant to acid-sensitive APIs, probiotics and therapies where gastric exposure should be minimized.
Multiparticulates, coated pellets and functional shell technologies can support sustained or staged release, expanding capsule use in chronic therapy and patient-centric dosing.
Prescription and pharmacy-dispensed medicines represent the largest application pool, while nutraceutical and healthcare-product demand continues to broaden capsule consumption.
Capsules are widely used across anti-infectives, gastrointestinal drugs, CNS therapies, oncology medicines and many generic products. Regulatory familiarity and scalable filling support large-volume use.
Pain, cold/flu, digestive and other OTC products use both hard and soft capsule formats, benefiting from convenient swallowing and strong consumer recognition.
Vitamins, botanicals, probiotics and dietary supplements are major users of gelatin, HPMC and pullulan capsules. Clean-label and vegan positioning is particularly important in this segment.
Hospitals use capsule dosage forms across inpatient and discharge medications, while specialty formulations may require delayed release, high-potency containment or pediatric dosing flexibility.
North America is the largest regional market, accounting for approximately 40% of 2025 revenue. The United States combines high pharmaceutical and nutraceutical consumption, advanced formulation R&D and strong demand for premium plant-based and functional capsule technologies.
Europe is a mature high-value market with strict pharmaceutical quality requirements and increasing interest in titanium-dioxide-free, vegetarian and clean-label formulations. Germany, France, Italy and the United Kingdom are major pharmaceutical manufacturing and consumption markets.
Asia-Pacific is the fastest-growing major region. India and China are major producers of generic medicines and empty capsules, while Japan maintains high quality standards and premium formulation demand. Local manufacturing supports strong unit growth.
Brazil, Mexico and Colombia anchor regional pharmaceutical and nutraceutical capsule demand. Growth follows expanding generic production, private healthcare and supplement consumption, while pricing remains highly competitive.
Gulf markets favor premium and halal/plant-based capsule options, while broader African demand is driven by essential medicines and growing local pharmaceutical manufacturing. Regional supply reliability remains an important purchasing factor.
Capsules are established dosage forms, but shell quality must be tightly controlled because dimensional variation, moisture and dissolution directly affect filling performance and final drug-product release.
| Quality / Regulatory Element | Current Context | Market Effect |
|---|---|---|
| FDA dosage-form terminology | FDA recognizes standard, coated, delayed-release, extended-release and liquid-filled capsule dosage forms in Structured Product Labeling. | Supports broad pharmaceutical use across multiple delivery profiles. |
| Gelatin-to-HPMC bridging | FDA product reviews document approved development programs that transitioned from hard gelatin to hypromellose capsules after comparative dissolution and bioavailability evaluation. | Demonstrates regulatory acceptance of HPMC when product performance is supported. |
| Dissolution performance | Current HPMC suppliers publish disintegration and pH-performance specifications and offer application-specific release designs. | Makes shell selection part of formulation development rather than only packaging. |
| Machinability | Capsules must run reliably on high-speed filling equipment without excessive splits, telescoping or dimensional defects. | Favors high-quality suppliers and integrated technical-service capabilities. |
| Customization and traceability | Color, opacity and printing help product identification and anti-counterfeiting while meeting regulatory restrictions on colorants. | Adds premium value and supports brand differentiation. |
Competition combines global high-capacity capsule manufacturers and cost-competitive regional producers. Scale, supply security, polymer technology, regulatory documentation and formulation support are key differentiators.
Lonza's Capsules & Health Ingredients business states that it has the largest global capsule manufacturing capacity and produces billions of capsules annually. The portfolio spans gelatin, plant-based and specialized release technologies.
ACG manufactures gelatin and vegetarian capsules and also supplies encapsulation machinery and packaging materials. Its current plant-based range includes immediate-release, liquid-fill, delayed-release and inhalation-focused HPMC systems.
Qualicaps competes through pharmaceutical-grade hard capsule manufacturing, global quality systems and strong positions in both gelatin and plant-derived capsule technologies.
Natural Capsules maintains an active publicly listed manufacturing business and continues to report financial and investment activity through 2025–2026, supporting India's growing capsule-production base.
Regional suppliers compete through cost, customization, local technical service and growing export capabilities across hard gelatin and plant-based capsule formats.
5–7 May 2026: ACG showcased a completely vegan capsule system at Vitafoods Europe 2026, centered on ACGcaps H+ cellulose-and-water HPMC capsules, plant-based pigments, vegan printed capsules and titanium-dioxide-free opacifiers.
2026 reporting cycle: Natural Capsules published FY2025–26 audited financial results and August 2026 investor materials, reflecting ongoing capacity and business development in India's capsule manufacturing industry.
October 2025: Lonza launched Organicaps, described in its 2025 annual report as the first USDA organic-certified plant-based immediate-release pullulan capsule available for purchase in North America.
2025: Lonza expanded its ACHIEV digital platform with a Product Configurator that helps pharmaceutical and nutraceutical customers select and customize capsule specifications and access quality and regulatory documentation.
The global Medicinal Capsules market is projected to grow from USD 2.64 billion in 2026 to USD 4.10 billion by 2034, at a 5.7% CAGR. Growth will be driven by pharmaceutical production, generic medicines, nutraceutical demand, plant-based shells and increasingly functional capsule technologies.
| Forecast Variable | Current Direction | Expected Effect Through 2034 |
|---|---|---|
| Generic pharmaceutical output | Global production continues to expand. | Supports high-volume hard-capsule demand. |
| Plant-based materials | HPMC and pullulan adoption is increasing. | Raises premium product mix. |
| Functional shells | Delayed-release and liquid-fill hard capsules are expanding. | Creates formulation-driven value growth. |
| Nutraceutical demand | Supplements increasingly use clean-label and vegan capsules. | Broadens non-prescription demand. |
| Asia-Pacific production | India and China are expanding local pharmaceutical and capsule manufacturing. | Creates strongest incremental unit growth. |
The study supports pharmaceutical formulation strategy, capsule procurement, manufacturing planning, product development and competitive benchmarking.
Market sizing combines bottom-up supplier, product, pricing and utilization analysis with top-down demand validation. Quantitative inputs include product volumes, formulation or assay mix, replenishment cycles, end-user structure, regional access, pricing and application intensity.
Primary research validates purchasing criteria, formulation or assay workflow, product differentiation, adoption barriers and competitive positioning. Secondary research prioritizes regulators, public research agencies, peer-reviewed evidence and official manufacturer information. Forecast assumptions are cross-checked against industry utilization, regulatory requirements, R&D investment and regional healthcare or laboratory capacity.
Forecasts incorporate empty-capsule volumes, hard-versus-soft mix, gelatin-versus-plant-based penetration, average selling values, pharmaceutical and nutraceutical production, release-profile mix and regional manufacturing growth. North America remains the largest value market, while Asia-Pacific receives the strongest unit-volume growth assumptions because of expanding pharmaceutical production.
The market was valued at USD 2.50 billion in 2025 and is estimated at USD 2.64 billion in 2026. It is projected to reach USD 4.10 billion by 2034, representing a 5.7% CAGR.
Hard Capsules are the largest product type because they support powders, granules, pellets and multiple pharmaceutical filling technologies.
North America is the largest region with approximately 40% of global revenue, while Asia-Pacific is the fastest-growing major region.
The market includes gelatin, HPMC/cellulose, pullulan and other specialty plant-based or functional polymers.
HPMC capsules are animal-free, low-moisture and suitable for hygroscopic or moisture-sensitive fills, while also supporting vegetarian and clean-label positioning.
Delayed-release capsules protect selected payloads from stomach acid and release later in the gastrointestinal tract, supporting acid-sensitive APIs and specialized drug-delivery requirements.
The report profiles Lonza/Capsugel, ACG Capsules, Qualicaps, Natural Capsules, Farmacapsulas, Healthcaps India, Jyoti Capsulations, Erawat Pharma, Suheung and CapsCanada.
The public overview uses 2025 as the base year, 2026 as the estimated year and 2026–2034 as the forecast period.
Display logos only where use is approved. A logo does not imply a public endorsement.
The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.
We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.
I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.
Their custom report on clinical trial trends was a helpful reference as we explored new indications.
As someone working on early product planning, I found their therapeutic-area briefs useful and easy to apply in our internal discussions.
We needed dependable data and a clearly presented market structure. The research gave us a practical starting point for our assessment.
Publish named testimonials only when the individual and organization have approved disclosure.
Review the report scope, forecast timeframe, methodology, and cited evidence before deciding whether the full study fits your requirement.
Coverage, segmentation, geography, and market boundaries are stated within the report.
Readers can review the published sources and evidence referenced in this market overview.
Base, estimated, and forecast years are shown to place the market outlook in context.
Each overview displays its report identifier and latest update date.
A structured view of market size, forecast outlook, segmentation, regional dynamics, competitive activity, and the research framework behind this study.
Review the market estimate, growth outlook, forecast direction, and key factors influencing future demand.
Understand the report’s defined segments, demand drivers, applications, end users, and market opportunities.
Assess regional performance, selected country context, and factors shaping adoption across major markets.
Explore company profiles, market positioning, and selected developments relevant to the market landscape.
Review key demand drivers, challenges, emerging opportunities, technology shifts, and factors influencing market direction.
Understand the report scope, market boundaries, research approach, and evidence referenced in the published market overview.
